What AXA Parenterals does

AXA Parenterals Ltd. is an Indian pharmaceutical manufacturer founded in 2004 and headquartered in Roorkee, Uttarakhand, that produces sterile parenteral preparations including large volume parenterals (LVP), small volume parenterals (SVP), ophthalmic preparations, respiratory products (respules), and critical care injectables. The company operates three branded divisions: AXACARE (hospital care and IV fluids in FFS polyethylene containers), BIOAXA (critical care injectables, ampoules, pre-filled syringes, respules), and LUMERA (ophthalmic eye care). Manufacturing is anchored on Form-Fill-Seal technology from Rommelag Germany and Weiler USA with Medigrade LDPE resin from Lyondell Basell, LG, and Ineos, enabling automated closed-circuit aseptic filling with no human touch, followed by a superheated sterilizer pass at 108°C. The Roorkee plant, built on 1,45,000 sq. ft. of land with 2,80,000 sq. ft. of constructed area, is designed per USFDA and EU guidelines and holds PIC/S and WHO-GMP certifications, with EU-GMP approval pending and approximately 100 marketing authorizations worldwide.

The company runs three concurrent go-to-market motions: a CDMO business serving major pharmaceutical companies (Biocon, Cipla, Intas, Unichem, B. Braun) with formulation development, manufacturing, technical, and regulatory support; branded ethical sales across domestic India via 500+ channel partners covering 25+ states and 18,000+ hospitals; and international operations exporting generics and managing marketing rights across Africa (Nigeria, Ghana, Uganda, Kenya, DRC, Ivory Coast, Guinea, Togo, Cameroon), CIS (Georgia, Kyrgyzstan, Uzbekistan, Tajikistan, Kazakhstan), and South East Asia (Myanmar, Vietnam, Philippines) via regional distributors and tenders. Production capacity stands at 50 million LVP bottles and 50 million SVP vials per year, plus 1 million respules per day.

Revenue mechanics combine product manufacturing and sales, contract manufacturing service fees, branded formulation marketing, and international licensing/tender income. In 2023, AXA launched a wholly-owned subsidiary, Heilsa Life Sciences Pvt. Ltd., focused on advanced critical care medicines including Propofol, liposomal amphotericin B, enoxaparin, and heparin, signaling a vertical expansion into higher-margin specialty injectables. The company is developing APL Unit-II targeted at highly regulated markets (Europe, Australia, UK, US) and has announced plans for a new infusion plant in southern India to mitigate logistics costs. AXA employs over 765 people globally, projected to reach 1,000 by end-2024, and claims consistent market growth above 35%.

Name

AXA Parenterals

Legal name

Axa Parenterals Ltd.

Website

https://axaparenterals.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

AXA Parenterals Ltd. is an Indian sterile parenteral manufacturer (Roorkee, Uttarakhand, founded 2004) producing LVP, SVP, ophthalmic, respiratory, and critical care injectables via Rommelag/Weiler Form-Fill-Seal technology, serving hospitals through 500+ domestic channel partners, international distributors across Africa, CIS, and South East Asia, and CDMO contracts with major pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Sterile parenteral manufacturing
• IV fluid production
• Contract pharmaceutical manufacturing
• Ophthalmic preparations
• Critical care injectables

Headquarters

HQ city

Roorkee

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Product Manufacturing & Sales: Manufacturing and marketing of sterile parenteral preparations, life-saving medicines and hospital products including I.V. fluids, infusions, ophthalmic preparations, respiratory preparations, and critical care products.
2. Contract Manufacturing Services (CDMO): Contract Development & Manufacturing Organization providing formulation development, manufacturing, technical capabilities, and regulatory support services to marketing companies across the globe.
3. Branded Ethical Formulations: Marketing of company's own branded products across domestic and international markets through multiple business divisions (AXACARE, BIOAXA, LUMERA).
4. International Business Operations: Export of generic products, marketing rights for AXA products, institution supply and tender business in international markets.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

AXA Parenterals Ltd. manufactures and markets sterile parenteral preparations, life-saving medicines, and hospital products from its facility in Roorkee, Uttarakhand, India. The product portfolio spans Large Volume Parenterals (LVP) such as IV fluids and infusions, Small Volume Parenterals (SVP), ophthalmic preparations, ear/nasal drops, respiratory respules, and critical care injectables. The company also operates a Contract Development & Manufacturing Organization (CDMO) arm offering formulation development, manufacturing, and regulatory support to pharmaceutical companies worldwide.

Product overview

AXA Parenterals is a pharmaceutical company manufacturing sterile parenteral preparations, IV fluids, and hospital products. The company operates three business divisions: AXACARE (hospital care products and IV fluids), BIOAXA (critical care injectable specialty division), and LUMERA (ophthalmic/eye care products). The product portfolio encompasses Large Volume Parenterals (LVP) including Dextrose, Sodium Chloride, Ringer's solutions; Small Volume Parenterals (SVP); eye drops; ear drops; nasal drops; respules (respiratory preparations); and injectable products. The company also offers contract manufacturing services through its CDMO operations and serves both domestic Indian and international markets.

Differentiator

Problem solved

Functional benefit

Brands

• AXACARE: Hospital care products division focusing on basic hospital care products and intravenous fluids in polyethylene containers manufactured under aseptic conditions using FFS technology. Products include maintenance solutions, replacement therapy electrolytes, Lactated ringer, Linezolid, Ciprofloxacin, Metronidazole, Ofloxacin and Levofloxacin.
• BIOAXA
• LUMERA

Products and services

• Fluid Therapy - LVP (Large Volume Parenterals) Large Volume Parenterals including Dextrose injections (5%, 10%, 25%), Sodium Chloride injections (0.9%, 0.45%, 0.33%, 0.22%), Ringer's Lactate, Ringer's Injection, multiple electrolytes with Dextrose, Dextran 40, Mannitol, Invert Sugar, and antibacterial/anti-fungal/anti-protozoal/analgesic infusions packaged in Medigrade LDPE containers. Produced using Form-Fill-Seal (FFS) technology at a capacity of 50 million bottles per annum.
• Bioaxa Injectables Critical care injectable products including anesthetic formulations (Bupivacaine, Lignocaine, Mepivacaine, Ropivacaine) and other injectables such as Meropenem, Imepenem, Piperacillin, Cephalosporins, Ceftriaxone, and other critical care medications. Covers liquid ampoules, liquid vial injections, and pre-filled syringes.
• Eye Drops (E/D Range) Ophthalmic eye drop preparations including Betamethasone combinations, Ciprofloxacin, Dexamethasone, Dorzolamide, Fluconazole, Gatifloxacin, Gentamicin, Moxifloxacin, Ofloxacin, Timolol, Tropicamide, and ophthalmic suspensions like Chloramphenicol and Fluoromethalone.
• Ear Drops Ear preparations for treatment of ear infections and inflammation, including combinations with Beclomethasone, Clotrimazole, Chloramphenicol, Ofloxacin, and Clotrimazole with Lignocaine.
• Nasal Drops Nasal drop preparations including Oxymetazoline Hydrochloride, Sodium Chloride 0.65%, and Xylometazoline ear/nasal drops.
• Respules Respiratory suspensions for inhalation therapy including Budesonide, Ipratropium Bromide, Fluticasone Propionate, Levosulbutamol, Sulbutamol, combination products with Formoterol, Mometasone, Salmeterol, and Tiotropium. Production capacity of 1 million Respules per day.
• Lumera Ophthalmic Products Dedicated eye care product line covering antiallergics, antiinfectives, anti-inflammatory, antiglaucoma, antioxidants, irrigation, and lubricant products for conditions including Dry Eye, Glaucoma, Cataract, Age-related Macular Degeneration (ARMD), and Diabetic Retinopathy.
• Contract Development & Manufacturing (CDMO) Services Contract Development & Manufacturing Organization (CDMO) services offered to pharmaceutical companies worldwide, providing formulation development, manufacturing, technical capabilities, and regulatory support services.

Quantifiable outcome

• 35%+ consistent market growth
• +5 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core, primary and secondary.

• Heilsa Life Sciences Pvt. Ltd.coreStrategic or Co-development Partner100% subsidiary of AXA Parenterals, committed to advancing healthcare and improving lives through innovative pharmaceutical solutions. Extended ability to manufacture critical medicines such as Propofol, Liposomal amphotericin B, Enoxaparin, Heparin, Levetiracetam, Milirinone, Pantoprazole-lyophilized.
• AMBICA INTERNATIONALprimaryChannel Partner/ Reseller/ DistributorLeading distributor in the Philippines for AXA's brands and products in South East Asian market.
• Y T K Trading CompanyprimaryChannel Partner/ Reseller/ DistributorBurmese-owned trading company responsible for developing the market for AXA's brands in Myanmar.
• French Connections (West Africa)secondaryChannel Partner/ Reseller/ DistributorStrategic decision to move along with French connections to cater to the complete Francophone market in West Africa.
• Local Partners (CIS)secondaryChannel Partner/ Reseller/ DistributorLocal partners for CIS markets to address language challenges, with plans to set up own marketing team in coming years.
• CDMO Partners (Various Pharmaceutical Companies)coreChannel Partner/ Reseller/ DistributorContract manufacturing partners for whom AXA provides formulation development, manufacturing, technical capabilities, and regulatory support. Client logos shown include Biocon, Cipla, Intas, Unichem, B. Braun and other pharmaceutical companies.
• LumeracoreStrategic or Co-development PartnerDedicated eye care division under AXA Parenterals focused on ophthalmic preparations and disease awareness for conditions like Dry Eye, Glaucoma, Cataract, ARMD, and Diabetic Retinopathy.
• Rommelag GermanycoreTechnology or IntegrationGlobal leader in FFS (Form-Fill-Seal) technology. Provides LVP and SVP machines for automated pharmaceutical manufacturing.
• Weiler USAcoreTechnology or IntegrationGlobal leader in FFS technology providing manufacturing equipment for LVP and SVP production.
• Lyondell Basell / LG / IneosprimaryTechnology or IntegrationSuppliers of Medigrade LDPE for pharmaceutical-grade container manufacturing.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Aurobindo Pharma: Large Indian pharmaceutical manufacturer with a significant sterile injectables portfolio including IV fluids and ampoules. Comparable to AXA on therapeutic categories (sterile parenterals, ophthalmic, critical care) and on end customers (hospitals, distributors), though at materially larger scale.
• Gland Pharma: India-headquartered sterile injectables manufacturer and CDMO with strong regulated-market penetration (US FDA-approved sites). Closest peer to AXA in business model — own-brand sterile injectables plus contract manufacturing — and competes for the same CDMO mandates from Indian and global pharma.
• Piramal Pharma Solutions: Indian CDMO offering sterile fill-finish and aseptic manufacturing services to global pharma. Highly comparable CDMO/contract manufacturing focus and similar customer base of large pharma sponsors looking for injectable capacity.
• Syngene International: Indian contract development and manufacturing organization with sterile injectables and biologics capabilities. Comparable as an Indian-headquartered CDMO serving global pharma sponsors; broader in biologics but overlapping in small-molecule sterile manufacturing.
• Akums Drugs & Pharmaceuticals: One of India's largest contract manufacturers of sterile and non-sterile dosage forms including IV fluids, injectables, and ophthalmics. Closely comparable CDMO + own-brand model with similar end-customer profile (Indian hospitals and global pharma).
• Strides Pharma Science: Indian pharmaceutical company with a focused sterile injectables platform serving regulated and emerging markets. Comparable on product categories (sterile injectables, ophthalmics) and on go-to-market across Africa and other emerging geographies.
• Suven Pharmaceuticals: Indian CRAMS/CDMO with sterile injectable development and manufacturing capabilities. Comparable as an India-based contract manufacturer serving global innovator and generic pharma customers.

Broad incumbents

• B. Braun: Global incumbent in sterile IV solutions, infusion therapy and medical devices, and an existing AXA CDMO partner. Comparable on product type (sterile parenterals, IV fluids) and as a competing supplier to hospitals globally, though at vastly larger scale and with its own manufacturing footprint.
• Fresenius Kabi: Global leader in sterile injectable pharmaceuticals, IV fluids, infusion therapy and clinical nutrition. Closest global incumbent competitor to AXA in IV fluids and injectable hospital products, with broader geographic and therapeutic reach.
• Zydus Lifesciences: Large Indian pharmaceutical group with a sterile injectables and biologics portfolio plus CDMO capabilities. Comparable on sterile injectable categories and on emerging-market distribution, but broader in scope across oral solids, APIs and biosimilars.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/LtdAxa
• Facebookfacebook.com/axapar
• LinkedInlinkedin.com/company/axa-parenterals-ltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AXA Parenterals